Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet's disease.
Behçet’s disease
autoantibodies
bullous pemphigoid
diagnosis
epitope spreading
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
07
2022
accepted:
12
09
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
Behçet's disease (BD) is a systemic inflammatory disease of unknown etiology. BD is characterized by relapsing oral and genital ulcers, several different cutaneous features, relapsing bilateral uveitis, and involvement of internal organs, showing vascular, gastrointestinal, and neurological manifestations. Serologically, BD is not characterized by disease-specific autoantibodies. In fact, only laboratory markers of inflammation, such as C-reactive protein, may be increased in association with increased disease activity. Bullous pemphigoid (BP) is an autoimmune disease characterized mainly by tense blisters and urticaria-like plaques on the skin. In addition, BP can involve oral mucosa in up to 20% of patients. Patients with BP show serum IgG autoantibodies against BP antigen 180 (BP180) and/or BP antigen 230 (BP230). Tissue-bound autoantibodies can be visualized as linear IgG staining along the basement membrane by direct immunofluorescence microscopy. In this report, we first described a young patient with BD who showed IgG autoantibodies against BP180 without developing blisters or urticaria-like plaques.
Identifiants
pubmed: 36341270
doi: 10.3389/fmed.2022.1001120
pmc: PMC9632984
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1001120Informations de copyright
Copyright © 2022 Didona, Sequeira Santos, Cunha, Hinterseher, Kussini and Hertl.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Acad Dermatol. 2021 Apr;84(4):1155-1157
pubmed: 32711089
J Dtsch Dermatol Ges. 2018 Nov;16(11):1339-1358
pubmed: 30395395
Front Med (Lausanne). 2022 Jun 09;9:875492
pubmed: 35755063
Acta Derm Venereol. 2019 Oct 1;99(11):1029-1030
pubmed: 31282977
Dermatologie (Heidelb). 2022 Sep;73(9):692-700
pubmed: 36006424
An Bras Dermatol. 2017 Jul-Aug;92(4):452-464
pubmed: 28954091
Front Immunol. 2019 Mar 29;10:665
pubmed: 30984205
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47
pubmed: 23441863
Front Immunol. 2018 Apr 17;9:779
pubmed: 29719538
Front Immunol. 2021 Mar 25;12:569287
pubmed: 33841390
J Dermatol Sci. 2002 Dec;30(3):224-32
pubmed: 12443845
Expert Rev Clin Immunol. 2017 Jan;13(1):57-65
pubmed: 27351485